KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EPS (Weighted Average and Diluted) (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of EPS (Weighted Average and Diluted) readings, the most recent being $0.31 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 72.22% to $0.31 in Q1 2026 year-over-year; TTM through Mar 2026 was $1.33, a 215.65% increase, with the full-year FY2025 number at $1.21, up 183.45% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.31 in Q1 2026 for Teva Pharmaceutical Industries, down from $0.41 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.41 in Q4 2023 to a low of -$1.17 in Q4 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.12 (2024), compared with a mean of -$0.16.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 1328.57% in 2022 and later soared 315.79% in 2025.
  • Teva Pharmaceutical Industries' EPS (Weighted Average and Diluted) stood at -$1.17 in 2022, then soared by 135.04% to $0.41 in 2023, then plummeted by 146.34% to -$0.19 in 2024, then soared by 315.79% to $0.41 in 2025, then decreased by 24.39% to $0.31 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.31 (Q1 2026), $0.41 (Q4 2025), and $0.37 (Q3 2025) per Business Quant data.